SGLT2 inhibitors to prevent diabetic kidney disease

Lancet Diabetes Endocrinol. 2020 Jan;8(1):4-5. doi: 10.1016/S2213-8587(19)30387-0.

Authors

Paola Fioretto¹, Roberto Vettor², Roberto Pontremoli³

Affiliations

¹ Department of Medicine, University of Padua, 35128 Padua, Italy. Electronic address: paola.fioretto@unipd.it.
² Department of Medicine, University of Padua, 35128 Padua, Italy.
³ Department of Internal Medicine, University of Genoa and IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

PMID: 31862151
DOI: 10.1016/S2213-8587(19)30387-0

No abstract available

MeSH terms

Diabetes Mellitus, Type 2 / complications*
Diabetic Nephropathies / prevention & control*
Humans
Observational Studies as Topic
Sodium-Glucose Transporter 2 Inhibitors / therapeutic use*
Treatment Outcome

Substances

Sodium-Glucose Transporter 2 Inhibitors